Navigation Links
Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
Date:3/6/2008

SEATTLE, March 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that it plans to issue earnings results for the fourth quarter and year ended Dec. 31, 2007, after the close of market on March 13, 2008. The company's earnings conference call will take place March 13, 2008, at 2 p.m. PDT (5 p.m. EDT).

Third-Quarter Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, March 13, 2008

Participants are invited to call 877-545-1491 or 719-325-4931. The live event will be available on Trubion's Web site at http://investors.trubion.com/events.cfm.

A replay of the discussion can be obtained beginning at 8 p.m. EDT March 13 by visiting Trubion's Web site or calling 888-203-1112 or 719-457-0820 and entering the code 7634379. The telephone replay will be available until midnight on Monday, March 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythema
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Trubion Announces Presentations at Upcoming Investor Conferences
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... WASHINGTON, Dec. 1 The... clinic in Los Angeles, has agreed to pay the Unit... received illegal kickbacks from HealthSouth Corpo... ,, The settlement resolves allegations that ...orm of stock option grants, donations to the Kerla...
(Date:12/1/2009)...ccreta is increasingly common but more easily iden...(HealthDay News) -- A magnetic resonance imaging ...tening pregnancy complication called placenta accr... when the placenta surrounding a fetus attaches to... placenta can pull out parts of the uterine wall, ...
(Date:12/1/2009)..., WASHINGTON, Dec. 1 Wi... a growing number of employers are providing self-...en enrollment season, according to a new survey by... majority of employers who offer these tools belie...an decisions. ,, According to the survey, 45 pe...
(Date:12/1/2009)..., BELLEVUE, Wash., Dec 1 Edifec...hcare Channel Modernization solutions announced an...at facilitates HIPAA 4010A1 to HIPAA 5010 migratio...0A1-5010 conversion maps, allows generation of tes...0A1 and 5010 in production, thus addressing most r...
(Date:12/1/2009)...ests that ,less affirming, isolating behaviors ju...c. 1 (HealthDay News) -- A new study suggests that...ence others to feel lonely, too. , "Loneliness ...o three degrees of separation," said James H. Fowl...er issue of the Journal of Personality and Social...
Breaking Medicine News(10 mins):Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Serious Pregnancy Complication Detected With MRI 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 3Health News:Loneliness May Be Catching 2Health News:Loneliness May Be Catching 3
...U.S. Food and Drug Administration (FDA) today appr...m tartrate) immediate-release tablets.// Zolpidem ... indicated for the short-term treatment of insomni...nd regulatory process," said Gary J. Buehler, dire...
...chocolate giants Cadbury have to pay heavily for t...he company had failed to inform the concerned auth...traces of bacteria in the samples of chocolates at...Regulations 2004. The Birmingham City Council...
...nternational meeting organized to thrash out issue...valuable //opportunity to focus attention on a bur...al communities. Amongst the Inuit population of Nu...rowned upon for their lack of attention on child i...
...r causing bugs may not be all that bad for you. Re...Helicobacter pylori to reduced chances of developi...ew York University School of Medicine, who publish... about asthma and allergy history. This involved a...
...archers from have found that infection with HIV, t... increased risk of myocardial infarction or heart ...sk factors were also increased in study participan... a higher incidence of myocardial infarction and m...
... deficiency anemia is the commonest medical disord...fetal health.// Despite several national programme...ng pregnancy, the success has not been as anticipa...Girls born underweight are at risk of producing sm...
Other Medicine News:Health News:FDA Approves First Generic Versions of Ambien for Insomnia 2Health News:Cadbury Indicted on Salmonella Scare 2Health News:Suicide - Aboriginal Communities Take Stock of the Killing Numbers 2Health News:Ulcer Causing Microbe Linked To Protection From Asthma 2Health News:HIV Infection Associated With Increased Risk of Heart Attack 2
(Date:12/1/2009)... , , LANSING, Mich., Dec. 1 /PRNewswire-Fi...nounced today that it has acquired the BioKits foo...robe Incorporated ( GPRO). The acquisition include...and fish speciation, and plant genetics. ,, Gen...cquisition of Tepnel Life Sciences plc in April 20...
(Date:12/1/2009)... , , ARLINGTON, Va., Dec. 1 /PRNewswi...f its newest report, The Market Outlook for Rese... appropriated to the NIH Scientific Research progr...ARRA) is being earmarked for lab renovations, Chal...nd research that spans multiple public and non-pro...
(Date:12/1/2009)... , , NEW YORK, Dec. 1 /PRNewswire-First...leading source of health information, today announ...wards. The fourth annual WebMD Health Heroes honor...courage and perseverance, who lead an effort to he... http://www.newscom.com/cgi-bin/prnh/20091201/NY...
Breaking Medicine Technology:Neogen Acquires Gen-Probe's BioKits Food Safety Business 2BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010 2BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010 3WebMD Announces 2009 Health Heroes 2WebMD Announces 2009 Health Heroes 3Aprima and MRM Partner to Bring Award Winning Electronic Health Record Solution to Practices in Tennessee Virginia 59337 1Aprima and MRM Partner to Bring Award Winning Electronic Health Record Solution to Practices in Tennessee Virginia 59337 2Aprima and MRM Partner to Bring Award Winning Electronic Health Record Solution to Practices in Tennessee Virginia 59337 3Humidifiers Not Just for Children Anymore AchooAllergy com Announces All New Humidifiers Offering 59335 1Humidifiers Not Just for Children Anymore AchooAllergy com Announces All New Humidifiers Offering 59335 2Humidifiers Not Just for Children Anymore AchooAllergy com Announces All New Humidifiers Offering 59335 3ADSC 26apos 3Bs Pain Management Reinforcement 59333 1ADSC 26apos 3Bs Pain Management Reinforcement 59333 2
...ifornia, June 4 BN,ImmunoTherapeutics, Inc. has i...apeutic vaccine candidate against prostate cancer....8 male patients with,non-metastatic as well as hor...nt in the US. Secondary objectives of the trial in...ce prostate antigen-specific immune,responses, as ...
... of the Dana-Farber Cancer Institute presents phas...al activity of perifosine in patients with relap...NEW YORK, June 3 Keryx Biopharmaceuticals,Inc. (N...s of perifosine,(KRX-0401) in patients with relaps...was presented at the 44th Annual Meeting of the,Am...
Other Medicine Technology:BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine 2Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 2Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 3Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 4Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 5Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology 6
COCOONReusableLower Torso
Model 522 - Upper Body Blanket
CritiCool™
...he OPMI VISU 210, Carl Zeiss has created a surgica...e state-of-the-art for ophthalmic surgery. Its wid...urgeons and it offers new functions to improve dep...pletely integrated assistant's microscope the OPMI...
Medicine Products: